Payment overview · 2025
General Payments
$560.39
14 reported records · 5 companies
Healthcare provider profile · identity verified
Keary Hinds, DNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · WEST MILFORD, NJ · NPI 1467157925
Verified facts
What the public records show
CMS Open Payments records show Keary Hinds, DNP received $560.39 in general payments during 2025 across 14 reported records.
Amgen Inc. accounted for 73.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $413.39 | 73.8% | 6 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $54.90 | 9.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.26 | 6.8% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.23 | 5.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.61 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $560.39 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $256.83 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $156.56 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $30.23 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 460 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 382 | 119 |
| Gabapentin | Gabapentin | 293 | 69 |
| Metformin Hcl | Metformin Hcl | 231 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 208 | 67 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 162 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 160 | 28 |
| Furosemide | Furosemide | 156 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 36 |
| Glimepiride | Glimepiride | 133 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 121 | 26 |
| Lisinopril | Lisinopril | 107 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 37 |
| Losartan Potassium | Losartan Potassium | 94 | 38 |
| Potassium Chloride | Potassium Chloride | 94 | 28 |
| Eliquis | Apixaban | 92 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 14 |
| Promethazine Hcl | Promethazine Hcl | 88 | 33 |
| Lorazepam | Lorazepam | 87 | 11 |
| Ibuprofen | Ibuprofen | 86 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 27 |
| Farxiga | Dapagliflozin Propanediol | 76 | 12 |
| Nifedipine Er | Nifedipine | 72 | 16 |
| Alprazolam | Alprazolam | 70 | 11 |
| Jardiance | Empagliflozin | 69 | 18 |
| Tramadol Hcl | Tramadol Hcl | 69 | 17 |
| Azithromycin | Azithromycin | 67 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 65 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 16 |
| Meloxicam | Meloxicam | 61 | 14 |
| Omeprazole | Omeprazole | 61 | 19 |
| Clonazepam | Clonazepam | 57 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 57 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 55 | 21 |
| Allopurinol | Allopurinol | 54 | 16 |
| Carvedilol | Carvedilol | 54 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 16 |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 22 |
| Prednisone | Prednisone | 46 | 13 |
| Trazodone Hcl | Trazodone Hcl | 46 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 20 |
| Kerendia | Finerenone | 43 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 41 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 41 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Methadone Hcl | Methadone Hcl | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Simvastatin | Simvastatin | 28 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | 12 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Famotidine | Famotidine | 24 | 11 |
| Diazepam | Diazepam | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | 11 |
| Linzess | Linaclotide | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Misoprostol | Misoprostol | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $560.39 · 14 records | Amgen Inc. | AIRSUPRA, BREZTRI, GVOKE HYPOPEN, KRYSTEXXA, Ozempic, REPATHA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error